Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
Vikram Ranade, PhD
Ranjan Batra, PhD
Oxana Beskrovnaya, PhD
- Vikram Ranade, PhD, appointed as chief business officer -
- Ranjan Batra, PhD, appointed as chief scientific officer -
- Oxana Beskrovnaya, PhD, transitioning to chief innovation officer -
WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointments of Vikram (Vik) Ranade, PhD, as chief business officer (CBO) and Ranjan (Ron) Batra, PhD, as chief scientific officer (CSO) of Dyne. Dr. Ranade will lead business development, corporate strategy and strategic partnerships to support the company's late-stage clinical and commercialization plans. Dr. Batra will lead the company's research strategy, pipeline development and activities supporting clinical development. Effective April 28, 2025, Oxana Beskrovnaya, PhD, will transition from CSO to chief innovation officer (CIO) responsible for driving Dyne's comprehensive innovation strategy to maximize the value of its FORCE™ platform and further enable the company's long-term success.
'I am excited to welcome Vik and Ron to our leadership team. Vik's experience in business development and corporate strategy will be invaluable as we prepare for the potential launches of two medicines in 2027 in myotonic dystrophy type 1 and Duchenne muscular dystrophy. Our incoming CSO, Ron, will play a key role in advancing our pipeline and elucidating the power of the FORCE platform to deliver functional improvement in the clinic,' said John Cox, president and chief executive officer of Dyne. 'With the addition of Vik, Ron and our CFO, Erick Lucera, as well as Oxana in her new role as CIO, we are well positioned to drive the business, deliver therapies that bring functional improvement to patients and create significant shareholder value through our clinical programs, pipeline and unique platform.'
Dr. Ranade joins Dyne, effective immediately, from Tessera Therapeutics, where he was senior vice president of corporate development, leading strategy and business development, and was member of the executive team. During more than five years at Tessera he also played a key role in equity financings totaling more than $600 million. Previously, he worked in McKinsey & Company's healthcare practice, advising biopharmaceutical and biotechnology companies on strategy, M&A and R&D. He led diligence on completed deals with an aggregate transaction value of more than $15 billion and advised on clinical strategy for more than 20 programs. Dr. Ranade also co-led McKinsey's Center for Asset Optimization, which focuses on clinical-stage asset development strategy. Dr. Ranade holds a PhD in Genetics and Development from Columbia University and a BS in biochemistry from Brandeis University, where he earned highest honors for his research on DNA damage repair pathways.
'I am thrilled to welcome Ron as our new scientific leader. He brings outstanding scientific expertise and the required peer network and passion to continue to expand Dyne's pipeline of potentially transformative therapies,' said Dr. Beskrovnaya. 'In my new role, I look forward to working with our strong leadership team and leveraging our world-class expertise in TfR1 delivery to pioneer and accelerate new therapeutic applications.'
Dr. Batra joins Dyne, effective April 28, 2025, from Lexeo Therapeutics, where he was vice president of research and translation. A leading expert in RNA biology and therapeutics, he has developed cutting-edge treatments for genetic diseases. Previously, Dr. Batra served as a senior vice president of R&D at LocanaBio, advancing RNA-targeted therapies for rare disorders including Duchenne muscular dystrophy and myotonic dystrophy. Prior to LocanaBio, he worked at Verily Life Sciences and conducted pioneering research at UC San Diego and the University of Florida with more than 35 publications and patents. Dr. Batra earned a PhD in genetics from the University of Florida, where he studied RNA biology and gene therapy for neuromuscular diseases.
About Dyne TherapeuticsDyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, the potential of DYNE-101 and DYNE-251, and expectations regarding the timing of commercial launches constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'objective,' 'ongoing,' 'plan,' 'predict,' 'project,' 'potential,' 'should,' or 'would,' or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne's ability to enroll patients in clinical trials; whether results from preclinical studies and data from clinical trials will be predictive of the final results of the clinical trials or other trials; whether data from clinical trials will support submission for regulatory approvals; uncertainties as to the FDA's and other regulatory authorities' interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and as to the regulatory approval process for Dyne's product candidates; whether Dyne's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne's filings with the Securities and Exchange Commission (SEC), including the Company's most recent Form 10-K and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release.
Contacts:
InvestorsMia Tobiasir@dyne-tx.com781-317-0353MediaStacy Nartkersnartker@dyne-tx.com781-317-1938
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/4829a611-e578-4503-b420-cca452b426c5
https://www.globenewswire.com/NewsRoom/AttachmentNg/9ebc562f-504a-4469-a1f7-5d1f919c55fe
https://www.globenewswire.com/NewsRoom/AttachmentNg/ed1431e9-0ccc-4953-92a4-9233a7187e86Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Is Apple Stock a Bad-News Buy?
Apple's stock is down significantly this year as multiple factors have been weighing down its valuation. The company's iPhone sales grew by just under 2% last quarter. Tariffs and a fumbled artificial intelligence strategy could further impact its near-term growth prospects. 10 stocks we like better than Apple › Shares of tech and consumer giant Apple (NASDAQ: AAPL) are down around 20% this year. That's not the type of performance investors would normally expect to see from the stock, unless there was a wide-scale sell-off in the tech sector. That's not the case this year. Instead, the stock has been underperforming the market and it hasn't been giving investors a reason to be optimistic about a turnaround taking place anytime soon. But despite all the negativity surrounding the stock, this is still Apple -- one of the strongest, most iconic, and most recognizable brands in the world. If it's crashing, should you consider loading up on the stock? There are, unfortunately, no shortage of headwinds facing Apple's business right now. The biggest one is arguably the slow rollout of its artificial intelligence (AI) features for its iPhones. Apple has pushed back on the release of some of its more advanced AI features until next year. It's a problematic situation given that its rivals already have AI-powered phones available on the market. Apple is focusing on privacy and keeping data secure, which is an increasingly important topic when it comes to AI. But investors still aren't impressed. Another problem is that Apple faces a lot of exposure to tariffs as it makes the vast majority of its products in China. The company is working on shifting production for iPhones that it sells in the U.S. to India, but it could take until the end of next year before capacity is ramped up sufficiently to accommodate U.S. demand and to minimize its Chinese exposure. But the uncertainty around tariffs is a big question mark as tariff rates have changed significantly this year. Investors are finding it easier to simply sell Apple's stock than to worry about all these factors. Apple is still around a $3 trillion market cap despite its poor start this year. But with a lower valuation, it's trading at 31 times its trailing earnings, which is now only slightly above its five-year average. While the sell-off may seem steep for one of the most valuable companies in the world, Apple would need to decline another 15% before getting near its 52-week low of $169.21. Paying 31 times earnings may be acceptable for a growth stock, but Apple's latest numbers weren't all that impressive. During the first three months of the year, the company's iPhone sales increased by just under 2% to $46.8 billion. Demand in the future may not get a whole lot stronger, either, especially if consumers become more price conscious due to concerns about a slowdown in the economy and need to tighten up their household budgets. Apple's business is still doing well as it posted a profit of $24.8 billion last quarter. But the problem is that at its current valuation, you would still be paying a high multiple for a business that's growing in just single digits. And with a possible slowdown looming, that makes it even harder to justify buying Apple's stock right now. This can still be a good long-term buy but I wouldn't consider buying shares of Apple unless it were to fall further in value. Due to its poor AI deployment and slow growth, investors should demand more of a discount for the stock as the business is facing a lot of uncertainty. While Apple isn't necessarily a bad investment over the long haul, there are better growth stocks to consider right now. Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple. The Motley Fool has a disclosure policy. Is Apple Stock a Bad-News Buy? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
St. Francis Hospital recognizes National Gun Violence Awareness Day
HARTFORD, Conn. (WTNH) — Friday is National Gun Violence Awareness Day. Guns are listed as the leading cause of death for children and teens in the United States and more than 100 Americans are killed with guns every day, according to the Centers for Disease Control and Prevention. Governor Lamont advocates for more funding for gun violence prevention Saint Francis Hospital hosted a ceremony and speaking program Friday morning to honor those who have been impacted by gun violence and raise awareness of the important day. 'On Jan. 29, 2013, Hadiya Pendleton, a 15-year-old high school sophomore was shot and killed while standing in harsh park in Kenwood, Chicago,' hospital president Valerie Powell-Stafford said. 'Her death drew a national spotlight and stands as a reminder of how easily and abruptly gun violence can disrupt lives. The 'Wear Orange' campaign for gun violence awareness runs through the weekend. You can wear something orange to show your support for the movement. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
The Memory Breath Introduces 3-Second Breathing Technique Inspired by Scientific Research on Mindful Focus
Dr. Brian Johnson Introduces Digital Breathing Program Aimed at Enhancing Mindful Focus Houston, June 06, 2025 (GLOBE NEWSWIRE) -- New non-invasive routine designed to promote clarity through breathwork Dr. Brian Johnson, a neuroscientist focused on sensory wellness innovation, today introduced , a digital breathwork program designed to support mindfulness and daily focus through a guided, research-informed technique. The program is centered on a simple, repeatable breathing pattern that encourages users to take a moment of intentional stillness. Dr. Johnson developed the method as part of a broader interest in brainwave-aligned breathing exercises, with the goal of offering individuals an accessible tool for supporting cognitive engagement during daily routines. "This breathing method invites people to slow down and become more aware of their mental space," said Dr. Johnson. "Our goal was to create something practical and accessible, grounded in emerging science about the role of intentional breathwork." Delivered in digital format, The Memory Breath includes instructional guidance and supporting materials intended to help users establish a daily practice. The non-ingestible approach requires no supplements or equipment and can be performed in any environment, making it adaptable to a variety of lifestyles. The program is currently available exclusively through About The Memory BreathThe Memory Breath is a digital breathwork program created by neuroscientist Dr. Brian Johnson. It focuses on helping users establish a daily rhythm of mindful breathing through a simplified technique that promotes clarity and calm. More information is available at MEDIA CONTACT INFORMATIONEmail: support@ Memory Breath Note: This press release is for informational purposes only. The information provided should not be considered medical advice. Individuals should consult with healthcare professionals before making any changes to their wellness routines. CONTACT: Email: support@
